Category: Oxford

AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D

Andrew Hopkins, antivirals, Artificial Intelligence, BioPharma, biopharma nl, biotech IPO, cancer drugs, Clinical Trials, Daily, exscientia, Oxford, SYN, Top Story, United Kingdom / October 4, 2021 October 4, 2021

Exscientia’s IPO and private placement raised $464 million to support its artificial intelligence-based approach to discovering and developing new drugs. In addition to partnerships with pharmaceutical companies, an alliance with the Bill & Melinda Gates Foundation is focused on developing antiviral drugs for future pandemics.

Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials

BioPharma, biopharma nl, Cambridge, cancer drugs, cancer immunotherapy, Clinical Trials, Daily, Massachusetts, Oxford, Pharma, SYN, Top Story, United Kingdom, Vaccitech, Werewolf Therapeutics / April 30, 2021 April 30, 2021

Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.

Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic

biopharma nl, Daily, Evox Therapeutics, News, Oxford, Rare diseases, SYN, Top Story, United Kingdom / February 21, 2021 February 21, 2021

In the past year, Evox Therapeutics has inked alliances with two big pharma companies. The Series C financing now positions the biotech to advance to the clinic with its own exosome-based therapies.

Startups see new promise in old insight about viruses to stop cancer

BioPharma, biopharma nl, California, Clinical Trials, Daily, News, Oncology, Oncolytic Virus, Oxford, Pittsburgh, Startups, SYN, Theolytics, Top Story / February 1, 2021 February 1, 2021

Researchers have known for decades that viruses can beat back cancer. But it’s been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys.